Results 31 to 40 of about 4,569 (133)

Progress in the pathogenesis of thyroid-associated ophthalmopathy and new drug development

Taiwan Journal of Ophthalmology, 2020
Thyroid-associated ophthalmopathy (TAO) is the most common extrathyroidal manifestation of toxic diffuse goiter (Graves' disease), also known as Graves' ophthalmopathy/orbitopathy. As an organ-specific autoimmune disease, the pathogenesis of TAO is still
Yazhuo Huang, Sijie Fang, Shuo Zhang, Huifang Zhou   +3 more
doaj   +1 more source

Postural variation of exophthalmometry in Graves′ ophthalmopathy

Indian Journal of Ophthalmology, 1990
30 patients with Graves′ ophthalmopathy were subjected to exophthalmometry in the upright and supine positions to determine if the difference in exophthalmometer readings in these two situations are significantly different and would help in ...
Asad Rajvardhan, Tewari H, Ahuja MMS, Mithal A   +3 more
doaj  

Pulse dexamethasone therapy versus pulse methylprednisolone therapy for treatment of Graves′s ophthalmopathy

Indian Journal of Endocrinology and Metabolism, 2013
Pulse methylprednisolone therapy is the recommended therapy for moderate to severe and active ophthalmopathy, but high dose pulse methylprednisolone therapy is marred by the chances of fulminant hepatic failure and the high cost of therapy. Dexamethasone
Rajeev Philip, Sanjay Saran, Manish Gutch, Pushpaltha Agroyia, Rajiv Tyagi, Keshavkumar Gupta   +5 more
doaj   +1 more source

Clinical evaluation of Graves ophthalmopathy [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2012
Introduction. Graves ophthalmopathy is an autoimmune disease, which is the consequence of thyroid dysfunction. Ocular manifestations occur in 50% of patients with Graves disease.
Janićijević-Petrović Mirjana A., Šarenac Tatjana, Srećković Sunčica, Janićijević Katarina, Petrović Marko, Vulović Dejan   +5 more
doaj   +1 more source

TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition (Adv. Sci. 4/2026)

Advanced Science, Volume 13, Issue 4, 19 January 2026.
An Allosteric Strategy for Thyroid Eye Disease This illustration depicts an aptamer (purple) binding to the target protein (white) at an allosteric site. This strategic binding induces a conformational change that acts as a shield, preventing pathogenic autoantibodies (red) from initiating the disease cascade, while leaving the protein's normal ...
Yanchen Zhang, Ende Wu, Weibin Liu, Ling Zeng, Neng Ling, Hongmei Wang, Zhixing Li, Shuang Yao, Tonghe Pan, Xuanwen Li, Yate Huang, Xiaojing Li, Yunhai Tu, Wentao Yan, Jianzhang Wu, Mao Ye, Wencan Wu   +16 more
wiley   +1 more source

Exploring the Therapeutic Mechanism of Xiehuo Pingtu San in Treating Thyroid Eye Disease Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation

International Journal of Endocrinology, Volume 2026, Issue 1, 2026.
Background Xiehuo Pingtu San (XHPTS) has been shown to be safe and effective in treating thyroid eye disease (TED), yet its underlying mechanisms remain unclear. This study aimed to elucidate the active ingredients of XHPTS and their therapeutic mechanisms in TED through network pharmacology, molecular docking, and molecular dynamics simulations ...
Ping Wang, Ruiyan Liu, Xin Shang, Yu Fu, Ying Wang, Shuxun Yan, Suraiya Saleem   +6 more
wiley   +1 more source

Early Low‐Dose Rituximab for Mild‐to‐Moderate Thyroid Eye Disease: A Preliminary Evaluation of Efficacy and Safety

International Journal of Endocrinology, Volume 2026, Issue 1, 2026.
Background Thyroid eye disease (TED) is an autoimmune inflammatory condition linked to thyroid dysfunction, which can result in disfigurement and potential vision loss. Recently, immunomodulatory therapies such as rituximab have demonstrated potential benefit in managing TED.
Ming Lu, Luqiang Wang, Xuelian Zhang, Suraiya Saleem   +3 more
wiley   +1 more source

Factors Influencing the Conversion of Ocular Myasthenia Gravis to Generalized Myasthenia Gravis: A Retrospective Cohort Study

Journal of Ophthalmology, Volume 2026, Issue 1, 2026.
Purpose The conversion rate of ocular myasthenia gravis (OMG) to generalized myasthenia gravis (GMG) lacks definitive predictors. Methods This retrospective cohort study analyzed data collected at Siriraj Hospital between January 2007 and December 2019 to identify factors influencing OMG generalization and the time to conversion. The records of 200 OMG
Wanicha Chuenkongkaew, Niphon Chirapapaisan, Pawimon Chatchutimakorn, Natthapon Rattanathamsakul, Manassawee Joradoln, Pawita Kongthanasomboon, Akarawit Eiamsamarng, Gábor Tóth   +7 more
wiley   +1 more source

PDGFRα+DPP4+ Fibroblasts‐Macrophage Crosstalk Induces Orbital Fibrosis in Treatment‐Resistant Thyroid Eye Disease via the GAS6‐AXL Pathway

Advanced Science, Volume 12, Issue 45, December 4, 2025.
This study elucidates macrophage‐induced orbital fibrosis in TED via the GAS6‐AXL pathway, a treatment‐resistant disorder lacking non‐surgical therapies. Using a novel patient cell‐derived orthotopic animal model of orbital fibrosis for TED, we repurpose an existing fibrosis therapy, addressing the absence of stable models and offering a potential ...
Lu Cheng, Jinwei Cheng, Guiling Liang, Xiaorui Wang, Yanwen Ge, Jiapei Liu, Luwei Cai, Hui Ying, Fenfen Wang, Jing Hu, Yufan Wang, Philipp E. Scherer, Ben Zhou, Mengle Shao, Fang Zhang   +14 more
wiley   +1 more source

Development and psychometric properties of the Thai Graves’ ophthalmopathy quality of life (GO-QOL) questionnaire

Journal of Patient-Reported Outcomes, 2019
Purpose To develop and assess the psychometric properties of the Thai version of the Graves’ Ophthalmopathy Quality of Life (GO-QOL) questionnaire. Background Graves’ ophthalmopathy (GO) is a chronic condition that causes negative self-image and impaired
Mingkwan Lumyongsatien, Benjama Keeratidamkerngsakul, Kanokrat Pornpanich, Sumalee Vangveeravong, Preamjit Saonanon, Damrong Wiwatwongwana, Pornchai Mahaisavariya, Orapan Aryasit, Krit Pongpirul   +8 more
doaj   +1 more source